Groprinosin (Inosine Pranobex)

Groprinosin is indicated for viral infections where immune support is beneficial.

• Herpes simplex virus infections (e.g., oral or genital lesions).
• Human papillomavirus (HPV) infections, including warts.
• Influenza and other acute respiratory viral infections.
• Chronic viral infections requiring immunostimulation, such as certain cases of cytomegalovirus.
• As an adjunct therapy in immunocompromised patients with viral disease.

The safety profile of Groprinosin includes both frequent mild reactions and rare serious events.

Common

• Nausea or stomach discomfort.
• Headache.
• Mild fever.
• Skin rash or itching.
• Elevated liver enzymes (asymptomatic).

Serious

• Severe allergic reaction (anaphylaxis).
• Significant liver dysfunction.
• Hematologic abnormalities such as neutropenia.
• Autoimmune flare‑ups.

Before prescribing Groprinosin, clinicians should evaluate several safety considerations.

• Assess liver function; the drug may affect hepatic enzymes.
• Use caution in patients with known hypersensitivity to inosine pranobex.
• Monitor blood counts during prolonged therapy.
• Consider potential effects on autoimmune conditions.
• Evaluate renal function in patients with severe kidney impairment.
• Discuss pregnancy and breastfeeding status, as safety data are limited.

Groprinosin may interact with other medicines, requiring attention to avoid adverse outcomes.

Avoid

• Concurrent use with immunosuppressive agents (e.g., high‑dose corticosteroids) that could counteract its immunostimulant effect.
• Combination with other antiviral drugs that share metabolic pathways, potentially increasing toxicity.

Use with caution

• Anticoagulants (e.g., warfarin) due to possible alteration of coagulation parameters.
• Hepatotoxic medications (e.g., acetaminophen at high doses) because of additive liver stress.
• Live vaccines, as enhanced immune response may affect vaccine efficacy.
• Drugs that prolong QT interval, given rare cardiac effects.